The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) along with the University of Delaware are pleased to announce $3M in Congressionally-directed funding from the National Institute of Standards and Technology (NIST) for new equipment which will support the advancement of biopharmaceutical manufacturing processes and provide expanded opportunities for workforce development.
鈥淲e are grateful for the continued financial support from NIST that will help establish additional testbeds for biomanufacturing innovation and provide critical infrastructure to advance workforce training,鈥 shares Kelvin H. Lee, NIIMBL institute director.
NIST Director Dr. Laurie E. Locascio, Senator Chris Coons, and Senator Tom Carper, came together with leaders from academia and industry to hold a press conference at NIIMBL headquarters on Tuesday, September 22, announcing the award along with their commitment to support the state鈥檚 bioeconomy ecosystem and further innovations in biopharmaceutical manufacturing to benefit the world.
鈥淔or each dollar of federal funds from NIST, the private sector has contributed more than three dollars to NIIMBL, which is a strong indication that NIIMBL works and delivers returns,鈥 Dr. Locascio said. 鈥淭he work NIIMBL leads helps make sure that breakthrough inventions don鈥檛 get stuck in labs or made overseas but get manufactured here in the United States.鈥